Summary: In Q1 2024, Zevra Therapeutics claimed constructive topline info from its section 2 research of KP1077 in idiopathic hypersomnia, demonstrating promising tolerance and early indicators of significant advantages. The complete results will be offered at Snooze 2024, and an … [Read more...]